-+ 0.00%
-+ 0.00%
-+ 0.00%

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Barchart·08/06/2026 15:15:00
Listen to the news

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.